Cargando…

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

CONTEXT: The therapeutic strategy in intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy (IT) is not well defined. Most patients are usually retreated by Bacillus Calmette-Guerin (BCG). AIMS: To evaluate the efficacy of intravesical chemotherapy (IC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serretta, Vincenzo, Sommatino, Francesco, Gesolfo, Cristina Scalici, Franco, Vito, Cicero, Giuseppe, Allegro, Rosalinda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310111/ https://www.ncbi.nlm.nih.gov/pubmed/25657538 http://dx.doi.org/10.4103/0974-7796.148582

Ejemplares similares

Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer
por: Di Maida, Fabrizio, et al.
Publicado: (2021)

Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
por: Magalhães, Joana C, et al.
Publicado: (2023)

Randomized study of intravesical pirarubicin chemotherapy with low and intermediate-risk nonmuscle-invasive bladder cancer in Japan: Comparison of a single immediate postoperative intravesical instillation with short-term adjuvant intravesical instillations after transurethral resection
por: Naya, Yoshio, et al.
Publicado: (2018)

Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder Cancer
por: Owusu, Richmond A., et al.
Publicado: (2013)

A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer
por: Ruan, Qiang, et al.
Publicado: (2021)

Intravesical chemotherapy in non-muscle-invasive bladder cancer
por: Porten, Sima P., et al.
Publicado: (2015)

Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer
por: Liu, J., et al.
Publicado: (2023)

The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer
por: Chen, Jian-Xin, et al.
Publicado: (2023)

Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression
por: Delto, Joan C., et al.
Publicado: (2013)

Intravesical Treatments of Bladder Cancer: Review
por: Shen, Zancong, et al.
Publicado: (2008)

Intravesical therapy for urothelial carcinoma of the bladder
por: Manoharan, M.
Publicado: (2011)

High frequency of bladder cancer after nephroureterectomy: justification for adjuvant intravesical treatment?
por: Mekayten, Matan, et al.
Publicado: (2018)

Current Researches on Nanodrug Delivery Systems in Bladder Cancer Intravesical Chemotherapy
por: Lu, Yilei, et al.
Publicado: (2022)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Intravesical Agents in the Treatment of Bladder Clots in Children
por: Della Corte, Marcello, et al.
Publicado: (2023)

Is Intravesical Bacillus Calmette-Guérin Therapy Superior to Chemotherapy for Intermediate-risk Non-muscle-invasive Bladder Cancer?: An Ongoing Debate
por: Han, Kyung-Sik, et al.
Publicado: (2015)

The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone After Bladder-Sparing Surgery in High-Risk Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Study
por: Zhou, Zhongbao, et al.
Publicado: (2021)

Clinical and biochemical markers of visceral adipose tissue activity: Body mass index, visceral adiposity index, leptin, adiponectin, and matrix metalloproteinase-3. Correlation with Gleason patterns 4 and 5 at prostate biopsy
por: Serretta, Vincenzo, et al.
Publicado: (2018)

Correlation of Male Overactive Bladder with Intravesical Prostatic Protrusion
por: Kim, Ki Hong, et al.
Publicado: (2010)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Intravesical therapy for bladder cancer in the pandemic of Covid-19
por: Teoh, Jeremy Y. C., et al.
Publicado: (2020)

Mucoadhesive Cationic Polypeptide Nanogel with Enhanced Penetration for Efficient Intravesical Chemotherapy of Bladder Cancer
por: Guo, Hui, et al.
Publicado: (2018)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer
por: Van Hattum, J. W., et al.
Publicado: (2022)

Thiolated Mesoporous Silica Nanoparticles as an Immunoadjuvant to Enhance Efficacy of Intravesical Chemotherapy for Bladder Cancer
por: Chen, Cheng‐Che, et al.
Publicado: (2023)

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence
por: Zhang, Jianglei, et al.
Publicado: (2021)

Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
por: Prasanna, Thiru, et al.
Publicado: (2017)

Intravesical Separation of the Urines
Publicado: (1905)

Comparing adverse effects, short term outcomes, and cost implications of hyperthermic intravesical chemotherapy with Mitomycin-C and intravesical bacillus Calmette–Guerin instillation (Moscow-I strain) in the management of intermediate and high-risk nonmuscle invasive bladder cancer
por: Thyavihally, Yuvaraja B., et al.
Publicado: (2021)

Squamous differentiation in pT1 bladder urothelial carcinoma predicts poor response for intravesical chemotherapy
por: Li, Gang, et al.
Publicado: (2017)

Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS
por: Plambeck, Benjamin D., et al.
Publicado: (2023)

The different predictive value of mean platelet volume-to-lymphocyte ratio for postoperative recurrence between non-muscular invasive bladder cancer patients treated with intravesical chemotherapy and intravesical chemohyperthermia
por: Wang, Chengbo, et al.
Publicado: (2023)

Emerging intravesical therapies for management of nonmuscle invasive bladder cancer
por: Tomaszewski, Jeffrey J, et al.
Publicado: (2010)

AB057. Intravesical laparoscopic harvest of bladder mucosa for urethroplasty
por: Ho, Son Fat, et al.
Publicado: (2015)

Review of intravesical therapies for bladder pain syndrome/interstitial cystitis
por: Cvach, Kristina, et al.
Publicado: (2015)

Intravesical chondroitin sulphate for interstitial cystitis/painful bladder syndrome
por: Downey, A, et al.
Publicado: (2015)

Bladder Uptake of Liposomes after Intravesical Administration Occurs by Endocytosis
por: Rajaganapathy, Bharathi Raja, et al.
Publicado: (2015)

Efficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies
por: Jin, Xun, et al.
Publicado: (2016)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7t8kgvj90pvoo0k1fddg0htk5v